Scholar Rock Holding Operating Margin Growth & History (SRRK)
Scholar Rock Holding's operating margin was −404.81% for fiscal 2022.
View full Scholar Rock Holding company overviewScholar Rock Holding annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-12-31 | −404.81% | +285.67 pp |
| 2021 | 2021-12-31 | −690.48% | −126.45 pp |
| 2020 | 2020-12-31 | −564.03% | −297.87 pp |
| 2019 | 2019-12-31 | −266.16% | — |
Scholar Rock Holding quarterly operating margin
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q1 2022 | 2022-03-31 | −20.89% | +557.00 pp |
| Q4 2021 | 2021-12-31 | −873.40% | −113.68 pp |
| Q3 2021 | 2021-09-30 | −678.57% | +99.11 pp |
| Q2 2021 | 2021-06-30 | −658.82% | −159.80 pp |
| Q1 2021 | 2021-03-31 | −577.89% | −226.12 pp |
| Q4 2020 | 2020-12-31 | −759.72% | −596.68 pp |
| Q3 2020 | 2020-09-30 | −777.68% | −419.36 pp |
| Q2 2020 | 2020-06-30 | −499.03% | −233.38 pp |
| Q1 2020 | 2020-03-31 | −351.77% | +25.02 pp |
| Q4 2019 | 2019-12-31 | −163.04% | — |
| Q3 2019 | 2019-09-30 | −358.32% | — |
| Q2 2019 | 2019-06-30 | −265.65% | — |
| Q1 2019 | 2019-03-31 | −376.79% | — |
Scholar Rock Holding operating margin trends
Between the periods ended 2019-12-31 and 2022-12-31, Scholar Rock Holding's operating margin decreased from −266.16% to −404.81%, a change of −138.65 percentage points. The latest reported quarter, Q1 2022, shows −20.89%.
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scholar Rock Holding source filings ↗Community posts
Scholar Rock wins FDA approval for muscle-targeted SMA treatment
Scholar Rock ($SRRK) received FDA approval for ISEMBYLD, its apitegromab treatment for spinal muscular atrophy, in patients aged two and older receiving SMN2-targeted therapy. The company plans to begin shipping the medicine within days. Th ...